Status:
COMPLETED
Finding of Optimal Dose for NT 201 in the Treatment of Glabellar Frown Lines
Lead Sponsor:
Merz Pharmaceuticals GmbH
Conditions:
Glabellar Frown Lines
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
NT 201 is a botulinum toxin type A preparation free of complexing proteins, i.e. free of proteins other than the active toxin. Injected into the muscle, NT 201 causes local weakening to full paralysis...
Eligibility Criteria
Inclusion
- Moderate to severe glabellar frown lines
Exclusion
- Previous insertion of permanent material in the glabellar area
- Neuromuscular function disease
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2007
Estimated Enrollment :
191 Patients enrolled
Trial Details
Trial ID
NCT00430586
Start Date
November 1 2006
End Date
August 1 2007
Last Update
August 3 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Merz Pharmaceuticals GmbH
Frankfurt, Germany, 60318